ALD518 + ALD518 + ALD518
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute GvHD
Conditions
Acute GvHD
Trial Timeline
Mar 1, 2012 → Mar 1, 2013
NCT ID
NCT01530256About ALD518 + ALD518 + ALD518
ALD518 + ALD518 + ALD518 is a phase 1/2 stage product being developed by CSL for Acute GvHD. The current trial status is terminated. This product is registered under clinical trial identifier NCT01530256. Target conditions include Acute GvHD.
What happened to similar drugs?
20 of 20 similar drugs in Acute GvHD were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01530256 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Acute GvHD